Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE study
- 17 May 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 182 (2) , 304-315
Abstract
Background Secukinumab is a fully human monoclonal antibody that selectively binds to and neutralises interleukin‐17A. Objective To assess the efficacy and safety of different maintenance‐dosing regimens of secukinumab 300 mg based on PASI response at Week 24 in patients with moderate to severe plaque psoriasis. Methods OPTIMISE was a randomised, open‐label, rater‐blinded Phase 3b study. Subjects (n=1,647) received secukinumab 300 mg at baseline, Weeks 1, 2, 3, and 4, and every 4 weeks (q4w) to Week 24. At Week 24, PASI 90 responders (n=1306) were randomised to secukinumab 300 mg q4w (n=644) or every 6 weeks (q6w, n=662) regimen to Week 52; PASI ≥75 to P=0.1013). Heavier subjects (≥90 kg) demonstrated numerically higher PASI 90 response with q2w (57.1%) vs q4w regimen (39.6%, P=0.1053). Conclusion Standard q4w dosing of secukinumab 300 mg is the optimal dosing regimen to achieve and maintain clear or almost clear skin. Subjects with body weight ≥90 kg not achieving PASI 90 at Week 24 may benefit from the q2w dosing regimen.Keywords
This publication has 28 references indexed in Scilit:
- Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US womenAnnals of the Rheumatic Diseases, 2013
- Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 yearsBritish Journal of Dermatology, 2012
- IL-17 signaling in host defense against Candida albicansImmunologic Research, 2011
- Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 ImmunityScience, 2011
- Psoriasis associated with ulcerative colitis and Crohn's diseaseJournal of the European Academy of Dermatology and Venereology, 2009
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2008
- Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patientsClinical Rheumatology, 2007
- Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologicsJournal of the American Academy of Dermatology, 2007